Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of
chronic liver disease worldwide directly related to the progressive increase in overweight and
obesity. The accumulation of lipids in patients with NAFLD contributes to the development of
insulin resistance, inflammatory response and oxidative stress in hepatocytes and an alteration of
the circulating lipid and glycaemic profile. However, to date there are no effective
pharmacological treatments for patients with NAFLD. Lifestyle changes and dietary
modifications aimed to weight loss are the best current alternatives, therefore, new approaches
should be considered. Resveratrol, a natural polyphenol of the stilbene group, is a potential
candidate to be aware of the management of NAFLD for its anti-inflammatory, antioxidant
properties, and calorie restriction-like effects.
Methods: In this review, the available information
on the potential therapeutic effects of resveratrol on NAFLD developed mainly in animal models
and in some clinical trials are summarize.
Results: In vitro and animal model studies have shown
beneficial effects of resveratrol treatment on NAFLD. Resveratrol reduces hepatic accumulation
of lipids and improves lipid and glycaemic metabolism. Some of the mechanisms of action are
the signalling pathways of AMP-activated protein kinase, sirtuin 1 and nuclear factor κB.
However, the results obtained in clinical trials are inconclusive.
preclinical trials have shown promising results of resveratrol against NALFD, the lack of clear
results in clinical trials makes necessary more studies with a larger number of patients and for a